The median progression free survival (PFS) in the capecitabine group was 5.7 months, compared with 8.5 months in the capecitabine/bevacizumab group and 8.4 months in the capecitabine/bevacizumab/mitomycin group. When capecitabine was compared with the combination of capecitabine and bevacizumab, the hazard ratio was 0.63 (95% CI 0.50-0.79, P<0.001).r
The median overall survival for both the capecitabine with or without bevacizumab was 18 months, when both agents were combined with mitomycin the median overall survival was 16.4 months. On multivariate analysis, treatment was not associated with overall survival.
The response rate (confirmed partial or complete response) for capecitabine alone was 30.3%, CB 38.1% and CBM 45.9%. When C was compared with CB, the difference was not statistically significant (p=0.16), however when C was compared with CBM the difference was statistically significant (p=0.006).
In terms of sub-group analysis, patients with a single site of metastases or hepatic metastases only derived a greater benefit from the addition of bevacizumab.
Ratings of overall quality of life were similar in all 3 groups at baseline, 3 weeks, 6 weeks and at progression.r
Kaplan-Meier curves of (A) Progression-free survival (B) Overall survivalr
© Journal of Clinical Oncology 2010